Indivior Pharmaceuticals, Inc. (INDV)
34.94
+0.11
(+0.32%)
USD |
NASDAQ |
Sep 04, 16:00
34.93
-0.01
(-0.03%)
Pre-Market: 20:00
Indivior Pharmaceuticals Research and Development Expense (Quarterly) : 7.00M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.00M |
| March 31, 2026 | 9.00M |
| December 31, 2025 | 17.00M |
| September 30, 2025 | 20.00M |
| June 30, 2025 | 21.00M |
| March 31, 2025 | 22.00M |
| December 31, 2024 | 31.00M |
| September 30, 2024 | 22.00M |
| June 30, 2024 | 26.00M |
| March 31, 2024 | 28.00M |
| December 31, 2023 | 30.00M |
| September 30, 2023 | 18.00M |
| June 30, 2023 | 32.00M |
| March 31, 2023 | 27.00M |
| December 31, 2022 | 29.00M |
| September 30, 2022 | 20.00M |
| June 30, 2022 | 14.00M |
| March 31, 2022 | 8.00M |
| December 31, 2021 | 19.00M |
| September 30, 2021 | 11.00M |
| June 30, 2021 | 13.00M |
| March 31, 2021 | 9.00M |
| December 31, 2020 | 14.00M |
| Date | Value |
|---|---|
| September 30, 2020 | 8.00M |
| June 30, 2020 | 8.00M |
| March 31, 2020 | 10.00M |
| December 31, 2019 | 17.00M |
| September 30, 2019 | 11.00M |
| June 30, 2019 | 13.00M |
| March 31, 2019 | 12.00M |
| December 31, 2018 | 17.00M |
| September 30, 2018 | 16.00M |
| June 30, 2018 | 18.00M |
| March 31, 2018 | 16.00M |
| December 31, 2017 | 22.00M |
| September 30, 2017 | 23.00M |
| June 30, 2017 | 19.00M |
| March 31, 2017 | 25.00M |
| December 31, 2016 | 32.00M |
| September 30, 2016 | 29.00M |
| June 30, 2016 | 28.00M |
| March 31, 2016 | 31.00M |
| December 31, 2015 | 58.00M |
| September 30, 2015 | 36.00M |
| June 30, 2015 | 34.00M |
| March 31, 2015 | 20.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Supernus Pharmaceuticals, Inc. | 29.06M |
| Liquidia Corp. | 16.88M |
| Corcept Therapeutics, Inc. | 53.89M |
| Harrow, Inc. | 8.072M |
| Collegium Pharmaceutical, Inc. | -- |